# Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis

> **NCT00556075** · PHASE2 · TERMINATED · sponsor: **Repros Therapeutics Inc.** · enrollment: 67 (actual)

## Conditions studied

- Endometriosis

## Interventions

- **DRUG:** Proellex 25 mg
- **DRUG:** Placebo
- **DRUG:** Proellex 50 mg

## Key facts

- **NCT ID:** NCT00556075
- **Lead sponsor:** Repros Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-11
- **Primary completion:** 2009-05
- **Final completion:** 2009-07
- **Target enrollment:** 67 (ACTUAL)
- **Why stopped:** Clinical hold for safety
- **Last updated:** 2014-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00556075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00556075, "Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis". Retrieved via MORVS 2026-11-03 from https://api.morvs.ai/clinical/NCT00556075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*